Aadi Bioscience, Inc. - Common Stock (AADI)

Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.

Aadi Bioscience halts its PRECISION1 trial of nab-sirolimus in solid tumors with TSC1/TSC2 mutations due to insufficient efficacy. The company will focus on maximizing Fyarro sales, pausing new enrollments in other trials, and reducing its R&D workforce to extend cash runway into late 2026.

These are three Russell 2000 stocks to sell before they damage your hard-earned investment portfolio in the long run.

AADI stock results show that Aadi Bioscience missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Shares of BioVie Inc. (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public offering. BioVie shares dipped 41.8% to $1.10 in pre-market trading Here are some other stocks moving in pre-market trading.

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with 

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to $30.95 on Friday.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 60 points on Friday. The Dow traded up 0.11% to 37,288.04 while the NASDAQ rose 0.45% to 14,827.63. The S&P 500 also rose, gaining, 0.06% to 4,722.55.

First Solar stock is rising on Friday as investors in FSLR react to a new "buy" rating and $211 price target from Jefferies.

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 75 points on Friday. The Dow traded down 0.20% to 37,173.96 while the NASDAQ rose 0.31% to 14,806.71. The S&P 500 also fell, dropping, 0.19% to 4,710.37.

Mangoceuticals stock is falling on Friday after the company put into effect a public offering for shares of MGRX.

Aadi Bioscience Inc (NASDAQ: AADI) shares are trading lower after the company released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 

Aadi Bioscience stock is taking a beating on Friday as investors in AADI react negatively to interim data from a clinical trial.

Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.